The ability to induce cell death of MHC-II-positive tumors by cytotoxic CD4+ T-cells was previously documented in a murine model of MHC-II-positive melanoma.48 However, the findings of that study have not been developed further into a therapy to engage CD4+ T-cells to destroy MHC-II-positive tumors. The gene discussed is CD4; the disease is melanoma.